Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Status in Breast Cancer: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline

被引：0
|
作者：
Hoda, Raza [1 ]
Bowman, Anita [2 ]
Zehir, Ahmet [1 ]
Brogi, Edi [1 ,3 ]
Ladanyi, Marc [1 ]
Arcila, Maria [1 ]
Wen, Hannah [1 ]
Ross, Dara [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Yeadon, PA USA
[3] Weill Cornell Med Coll, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
185
引用
收藏
页码：175 / 177
页数：3
相关论文
共 50 条
  • [41] Histologic analysis according to HER2 gene status in HER2 2+invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations
    Hwang, Hye Won
    Hong, Soon Auck
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Yu, Jong-Han
    Lee, Se Kyung
    Cho, Soo Youn
    Cho, Eun Yoon
    VIRCHOWS ARCHIV, 2022, 480 (04) : 749 - 758
  • [42] Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)
    van de Vijver, MJ
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S11 - S17
  • [43] The ASCO/CAP guideline update for HER2 testing increases the number of breast cancer patients eligible for HER2-targeted therapy
    Giacomazzi, Juliana
    Hartmann, Carolina R.
    Paskulin, Diego D.
    Rivero, Luis Fernando
    Caleffi, Maira
    Pasqualotto, Alessandro C.
    Graudenz, Marcia S.
    Rosa, Daniela D.
    CANCER RESEARCH, 2015, 75
  • [44] Clinical Utility of HER2/ERBB2 Copy Number Analysis by Next Generation Sequencing in Metastatic Breast Cancer
    Xia, Daniel
    Kuo, Frank
    Dillon, Deborah
    MODERN PATHOLOGY, 2018, 31 : 113 - 113
  • [45] Clinical Utility of HER2/ERBB2 Copy Number Analysis by Next Generation Sequencing in Metastatic Breast Cancer
    Xia, Daniel
    Kuo, Frank
    Dillon, Deborah
    LABORATORY INVESTIGATION, 2018, 98 : 113 - 113
  • [46] NEU(C-ERBB2/HER2) AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) IN BREAST-CANCER
    JARDINES, L
    WEISS, M
    FOWBLE, B
    GREENE, M
    PATHOBIOLOGY, 1993, 61 (5-6) : 268 - 282
  • [47] Impact of the 2013 ASCO/CAP Guideline Recommendations for HER2 Testing of Invasive Breast Carcinoma: A Focus on Tumors Assessed as Equivocal for HER2 Gene Amplification By FISH
    Bethune, Gillian
    van Zanten, Daniel Veldheijzen
    Younis, Tallal
    Rayson, Daniel
    Thompson, Kara
    Barnes, Penny
    MODERN PATHOLOGY, 2015, 28 : 35A - 35A
  • [48] HER2/ERBB2 status in "HER2 equivocal" breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci
    Press, M. F.
    Seoane, J. A.
    Curtis, C.
    Quinaux, E.
    Guzman, R.
    Sauter, G.
    Eiermann, W.
    Mackey, J. R.
    Robert, N.
    Pienkowski, T.
    Crown, J.
    Martin, M.
    Valero, V.
    Bee, V.
    Ma, Y.
    Villalobos, I.
    Slamon, D. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
    Riecke, Kerstin
    Witzel, Isabell
    BREAST CARE, 2020, 15 (06) : 579 - 585
  • [50] Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling.
    Brufsky, Adam
    Crozier, Jennifer A.
    Chuba, Paul J.
    Lee, Sung Ho
    Menicucci, Andrea
    Kling, Heather M.
    Yoder, Erin
    Audeh, William
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345